绥美凯需要空腹服用吗？

(Dolutegravir tablets) is China's first compound single tablet for the treatment of AIDS. Each tablet contains 50 mg dolutegravir + 600 mg abacavir + 300 mg lamivudine. In order to achieve good results, does SuimeiKai need to be taken on an empty stomach?

From a pharmacokinetic perspective, Trimax may be taken with or without food. For adults or adolescents weighing more than 40kg, the recommended dose of SuimeiKai is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Trimax as it is a fixed-dose tablet and cannot be reduced.

For pregnant and lactating women, animal data and clinical experience in pregnant women should be considered when deciding to use antiretroviral drugs to treat HIV infection in pregnant women to reduce the risk of vertical transmission of HIV to the newborn. There are no data on the use of Trimax in pregnant women. Data on the use of dolutegravir in pregnant women are limited or non-existent. The effects of dolutegravir on human pregnancy are unknown. Therefore, caution is required when actually using this drug for treatment.

For the elderly population, there are limited data on the use of dolutegravir, abacavir, and lamivudine in patients 65 years and older. There is no evidence that older patients require different dosages than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using Trimax in this age group.

In Children, the safety and effectiveness of dolutea (dolutea) in children under 12 years of age has not been established. Trimax contains dolutegravir, abacavir, and lamivudine; therefore, interactions seen with these drugs when used alone are related to this product. No clinically significant drug interactions are expected between dolutegravir, abacavir, and lamivudine. No other specific symptoms or signs have been noted following acute overdose of dolutegravir, abacavir, or lamivudine.

Recommended hot articles: /newsDetail/83772.html